Additionally, dual agonists such as pemvidutide and survodutide, which target both GLP-1 and glucagon receptors, have demonstrated substantial reductions in hepatic steatosis, liver stiffness, and biomarkers of liver fibrosis [163,164]. This evidence concerns the gene GLP1R and fatty liver disease.